THE INSULINE-LIKE GROWTH FACTOR SYSTEM IN OVARIAN CANCER METASTASIS: THE RELATION WITH P45 SER Β-CATENIN

DOI: https://doi.org/None

N.V. Yunusova (1,2), I.V. Kondakova (1), L.A. Kolomiets (1,2), A.B. Villert (1) 1 -Cancer Research Institute of Siberian Вranch of the Russian Academy of Sciences, Kooperativny str., 5, Tomsk, Russian Federation, 634009; 2 -Siberian State Medical University, Moskovsky Trakt, 2, Tomsk, Russian Federation, 634050

Introduction: Insulin-like growth factors (IGFs), insulin-like growth factor-I receptor (IGF-IR), IGR-binding proteins (IGFBPs) and IGBP proteases can play an important role in the development of metastases in ovarian cancer. The relationship between IGF system proteins and p45 Ser β-catenin can be one of the mechanisms leading to metastatic disease. The purpose of the study was to analyze the expression of IGF system proteins in primary tumors, metastases and ascitic fluid in ovarian cancer patients as well as to detect the relationship between these proteins and p45 Ser β-catenin. Results. The contents of IGF system components and p45 Ser β-catenin in primary tumor tissue, ovarian cancer metastases and in ascitic fluid were analyzed in 25 patients with high-grade serous ovarian carcinoma. The data obtained showed high concentrations of IGFs and IGFBPs in ascitic fluid and heterogeneity of peritoneal and omental metastases in relation to the levels of PAPP-A metalloproteinase hydrolyzing many IGFBPs as well as the increased IGF-II level in primary tumor tissue as compared to that observed in omental metastases. The level of p45 Ser β-catenin in metastases was significantly decreased compared to the that in primary tumor. Conclusion. The relationship between p45 Ser β-catenin and the levels of IGF-IR, PAPP-A metalloproteinase and IGFBP-4 allows us to suggest the mechanisms of interaction of IGF system proteins mechanisms with motility associated molecules in metastatic ovarian cancer.
Keywords: 
insulin-like growth factors, insulin-like growth factor receptor I type, p45 Ser β-catenin, ovarian cancer, metastasis
Список литературы: 
  1. Bochkareva N.V., Kondakova I.V., Kolomiec L.A., Chernyshova A.L. Insulinopodobnye faktory rosta i svyazyvayushhie ih belki v patogeneze raka e`ndometriya. Cib. onkol. zhurn. 2008; 3 (27): 86–93. [Bochkareva N.V., Kondakova I.V., Kolomiets L.A., Chernyshova A.L. Insulin-like growth factors and insulin-like growth factor binding proteins in pathogenesis of endometrial cancer. Sibirskiy onkologicheskiy zhurnal. 2008; 3 (27): 86–93 (in Russian)]
  2. Samani A.A., Yakar S., Leroith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insight. Endocrine Reviews. 2007; 28 (1): 20–47.
  3. Yunusova N.V., Spirina L.V., Kondakova I.V., Kolomiets L.A., Chernyshova A.L., Koval V.D., Nedosekov V.V., Savenkova O.V. Relationship between the expression levels of PAPP-A metalloproteinase and growth and transcriptional factors in endometrial cancer. Biology Bulletin. 2013; 40 (3): 253–9.
  4. Pennisi A.P., Barr V., Nunez N.P. Reduced expression of insuline-like growth factor I receptors in MCF breast cancer cells leads to a more metastatic phenotype. Cancer Research. 2002; 62: 6529–37.
  5. Bourguignon L.Y., Peyrollier K., Gilad E., Brightman A. Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. J. Biol. Chem. 2007; 282 (2): 1265–80.
  6. Vinokurov V.L. Rak yaichnikov: zakonomernosti metastazirovaniya: vybor adekvatnogo lecheniya bol`nyh. Cpb.: FOLIANT. 2004. 336 c. [Vinokurov V.L. Ovarian cancer: regularities of metastasis and choice of adequate treatment of patients. Spb.: 2004 (in Russian)]
  7. Sodek K.L., Murphy K.J., Brown T.J. , Ringuette M.J. Cell–cell and cell–matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev. 2012; 31 (1–2): 397–414.
  8. Lane D., Robert V., Grondin R., Rancourt C., Piche A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int. J. Cancer. 2007; 121 (6): 1227–37.
  9. Stadlmann S., Amberger A., Pollheimer J., Gastl G., Offner F.A., Margreiter R., Zeimet A.G. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol. Oncol. 2005; 97 (3): 784–9.
  10. Verhaak R.G.W., Tamayo P., Yang J-Y. et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 2013; 123 (1): 517–25.
  11. Lafiti A., Luwor R., Bilandzic M., Nazaretian S., Stenvers K., Pyman J., Zhu H., Thompson E.W., Quinn M.A., Findlay J.K., Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 7(10):e46858 Published online 2012 October 8. doi: 10.1371/journal.pone.0046858.
  12. Spentzos D., Cannistra S.A., Grall F., Levine D.A., Pillay K., Libermann T.A., Mantzoros C.S. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocrine-Related Cancer. 2007; 14: 781–90.
  13. Huang G.S. , Brouwer-Visser J., Ramirez M.J., Kim C.H., Hebert T.M., Lin J., Arias-Pulido H., Qualls C.R., Prossnitz E.R., Goldberg G.L., Smith H.O., Horwitz S.B. Insulin-like growth factor 2 expression modulates taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin. Cancer Res. 2010; 16 (11): 2999–3010.
  14. Lu L., Katsaros D., Wiley A., Rigault de la Longrais I.A., Risch H.A., Puopolo M., Yu H. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen-receptor-alpha expression to the disease progression in epithelial ovarian cancer. Clin. Cancer Res. 2006; 12 (4): 1208–14.
  15. Bold H.B., Conover C. A. Overexpression of pregnancy-associated plasma protein-A in ovarian cancer. Endocrinology. 2011; 152 (4): 1470–8.
  16. King E.R., Zu Z., Tsang Y.T., Deavers M.T., Malpica A., Mok S.C., Gershenson D.M., Wong K.K. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol. 2011; 123 (1): 13–8.
  17. An Y., Cai Y., Guan Y., Cai L., Yang Y., Feng X., Zheng J. Inhibitory effect of small interfering RNA targeting insulin-like growth factor-I receptor in ovarian cancer OVCAR3 cells. Cancer Biother. Radiopharm. 2010; 25 (5): 545–52.
  18. Gest C., Mirshahi P., Li H., Pritchard L.L., Joimel U., Blot E., Chidiac J., Poletto B., Vannier J.P., Varin R., Mirshahi M., Cazin L., Pujade-Lauraine E., Soria J., Soria C. Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets. Cancer Lett. 2012; 317 (2): 207–17.
  19. van der Gun B.T.F., Melchers L.J., Ruiters M.H.J., Leij L.F., McLaughlin M.J., Rost G. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis. 2010; 31 (11): 1913–21.
  20. Taurin S., Sandbo N., Qin Y. et al. Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase. The J. of Biological Chemistry. 2006; 281 (15): 9971–6.
  21. Resch Z.T., Oxvig C., Bale L.K., Conover C.A. Stress-activated signaling pathways mediate the stimulation of pregnancy-associated plasma protein-A expression in cultured human fibroblasts. Endocrinology. 2006; 147 (2): 885–90.
  22. Ueno K., Hirata H., Majid S. et al. IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma. Int. J. Cancer. 2011; 129 (10): 2360–9.